Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies including NEO-PV-01, a clinical-stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of hormone receptor-positive (HR+) breast cancer.
Company profile
Website
CEO
Hugh O'Dowd
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Neon Securities Corporation ...
Latest filings (excl ownership)
15-12B
Securities registration termination
18 May 20
EFFECT
Notice of effectiveness
14 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 20
POS AM
Prospectus update (post-effective amendment)
6 May 20
8-K
BioNTech Completes Acquisition of Neon Therapeutics
6 May 20
25-NSE
Exchange delisting
6 May 20
8-K
Submission of Matters to a Vote of Security Holders
5 May 20
10-Q
2020 Q1
Quarterly report
1 May 20
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|